<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89069">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01943552</url>
  </required_header>
  <id_info>
    <org_study_id>244.2514</org_study_id>
    <nct_id>NCT01943552</nct_id>
  </id_info>
  <brief_title>Ipratropium Bromide in Peri-Operative COPD</brief_title>
  <official_title>Peri-operative Intervention With Nebulized Ipratropium Bromide in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>China: China Food and Drug Administration (CFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-group, multi-centre
      trial.The trial aims to evaluate efficacy of nebulized ipratropium bromide in Chinese
      peri-operative patients with COPD under general anaesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change of FEV1 from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment Day 3)</measure>
    <time_frame>treatment day 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of FVC from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment Day 3)</measure>
    <time_frame>treatment day 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main post-operative pulmonary complications (including pneumonia, atelectasis and acute respiratory failure) within three weeks after the surgery</measure>
    <time_frame>25 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood gas analyses from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment Day 3): arterial oxygen tension (PaO2) value, arterial oxygen saturation and arterial carbon dioxide tension (paCO2) value</measure>
    <time_frame>treatment day 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>ipratropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mcg four times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ipratropium bromide</intervention_name>
    <description>ipratropium bromide</description>
    <arm_group_label>ipratropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  All patients must sign an informed consent.

          -  Male or female patients aged &gt;= 50 years and &lt;= 75 years

          -  Patients must be current or ex-smokers with a smoking history of &gt;= 10 pack-years.

          -  All patients must be diagnosed with COPD and must meet the following spirometric
             criterion: post-bronchodilator forced expiratory volume in 1 second (FEV1) &lt; 70% of
             forced vital capacity (FVC) at Screening Visit (Visit 1).

          -  All patients have relatively stable COPD (i.e. have no COPD exacerbation within 4
             weeks prior to Screening Visit).

          -  All patients are about to receive selective surgical procedures of lobectomy or right
             bilobectomy under general anaesthesia, whilst the estimated time of surgical
             procedures lasts for not less than 2 hours, and the estimated time of general
             anaesthesia lasts for not less than 3 hours and not longer than 5 hours.

          -  Patients must be able to perform all study related procedures including technically
             acceptable pulmonary function tests (PFTs).

        Exclusion criteria:

          -  Patients who need maintenance treatment of bronchodilators (including
             anticholinergics, ß-agonists, xanthines).

          -  Patients with a recent history (i.e. six months or less) of myocardial infarction

          -  Patients with any unstable or life-threatening cardiac arrhythmia requiring
             intervention or change in drug therapy during the last year

          -  Patients with symptomatic chronic heart failure (i.e. New York Heart Association
             functional class III-IV)

          -  Known narrow angle glaucoma

          -  Patients with prostatic hyperplasia or bladder neck obstruction with significant
             symptoms

          -  Patients with a history of asthma, allergic rhinitis or who have a blood eosinophil
             count &gt;= 600 / mm3 (0.6×10^9/L). A repeat eosinophil count will not be conducted in
             these patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>244.2514.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>244.2514.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>244.2514.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>244.2514.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>244.2514.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>244.2514.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>244.2514.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>244.2514.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
